SLC1A1 and demyelinating disease: These findings imply that EAAT3‐targeting approaches may have therapeutic benefits in the management of demyelinating diseases or other neurological conditions involving white matter abnormalities, but further research including using conditional knockout mice is required to clarify the intricate interplay between the role of oligodendroglial‐specific EAAT3 in white matter repair and remyelinating function.